Harrow has given shareholders a bumpy ride lately, which puts fresh attention on a simple question for you as an investor.

Harrow is rated Sell due to reliance on aggressive H2 2026 guidance unsupported by cash and operational performance. Read ...

Nurse Harrow is now playable in Deadlock. Learn about her abilities, lore, and role as the final hero released in the City Never Sleeps update.

Boll stated, "we are updating our full year revenue outlook to a range of $270 million to $280 million." He noted, "While our original target is still within reach, this new range is one I believe we ...

Nurse Harrow has stepped into Deadlock, becoming the sixth and final hero to join the game and bringing the successful City ...

Harrow Inc (NASDAQ:HROW) and Taiwan-based Formosa Pharmaceuticals announced a licensing agreement on Monday. Harrow acquired the exclusive U.S. commercial rights for BYQLOVI (clobetasol propionate ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Was the transaction executed via direct or indirect ownership, and what entities were involved? All shares were disposed of indirectly through Opaleye, L.P. and a separately managed account, with ...

Harrow has the U.S. commercial rights to 10 branded ophthalmic pharmaceutical products approved by the Food and Drug Administration (FDA). Harrow also owns ImprimisRx, a leading U.S.